C ystic fibrosis (CF) is caused by mutations in the CF gene protein, the cystic fibrosis transmembrane conductance regulator (CFTR). 1 By far the most common mutation is DF508, present on 70-80% of chromosomes worldwide. Wild type CFTR resides at the apical membrane of epithelial cells where it acts as a cyclic AMP-dependent Cl 2 channel 1 and regulates other ion channels 2 and protein secretion. 3 Defective trafficking of DF508-CFTR leads to abnormal retention of mutant protein within the cell and consequent loss of CFTR function. 1 The reported degree of mislocalisation of DF508-CFTR in native epithelial cells varies between different tissues and types of preparation. [4] [5] [6] [7] More recently we and others have developed a technique to study the location of CFTR in freshly isolated native airway epithelial cells from patients with CF which allows quantitation of the percentage of cells with a defined CFTR location. 8 9 We have shown a marked mislocalisation of DF508-CFTR which was corrected by the CFTR activating benzo[c]quinolizinium compounds. 8 Thus, although our studies and those of others suggest that at least some DF508-CFTR traffics to the apical membrane in native CF cells, [7] [8] [9] the finding that the majority of DF508-CFTR is mislocalised 8 emphasises that moving DF508-CFTR to the apical membrane is necessary for developing a drug treatment targeted at CFTR rescue.
Arising from our earlier studies showing correction of antibody inhibited CFTR function by cyclic nucleotide phosphodiesterase (PDE) inhibitors, 10 we now show that the PDE5 inhibitor sildenafil (Viagra) increases DF508-CFTR trafficking. Since this is a drug in clinical use that causes rapid movement of DF508-CFTR from within the cell to the apical membrane, the results represent a major step forward in the development of a treatment that addresses the basic cellular abnormality for the majority of patients with CF.
METHODS

Patients and cell sampling
Airway epithelial cells were obtained by nasal brushing from three non-CF individuals (age 9-22 years) and from six CF individuals (age 6 months to 16 years) undergoing flexible bronchoscopy under sedation as previously described. 8 The CF individuals had the following genotypes: four DF508/ DF508, one DF508/4016ins, and one R1283M/E60X. The study was approved by the local ethics committee of Bro Taf Health Authority.
CFTR localisation in nasal epithelial cells
Immediately following nasal brushing, the brushes were placed in DMEM/F12 medium and the attached cells incubated in the presence or absence of sildenafil (150 mM) for 2 hours at 37˚C. Cells were then fixed and CFTR localised by immunofluorescence as previously described. 8 Briefly, after incubation, cells were smeared gently onto ''Snowcoat X-tra'' microslides (Surgipath), left to air dry, fixed for 5 minutes at 220˚C in 5% acetic acid in ethanol, washed in phosphate buffered saline (PBS) containing (in mM): 137 NaCl, 2.7 KCl, 4.3 Na 2 HPO 4 , 1.4 KH 2 PO 4 , pH 7.4 and stored at 220˚C. Following treatment with blocking reagent (normal rabbit serum 1:20), cells were incubated with primary antibody overnight at 4˚C, washed three times, and incubated with FITC conjugated secondary antibody (1:100) for 30 minutes at room temperature. The CFTR antibody used was our well characterised anti-CFTR antibody MPCT1 (affinity purified C-terminal; 1:100). 8 Slides were then mounted in Fluorosave Reagent (Calbiochem, La Jolla, CA, USA) and fluorescence was detected using confocal laser scanning microscopy on a Leitz DMRBE microscope (Leica, Germany) fitted with a TCS4D scanner (Leica, Germany).
Measurement of chloride transport activity in CF15 cells
The SV40 transformed nasal epithelial cell line JME/CF15 from a patient with CF (DF508/DF508) 11 was cultured in DMEM/F12 supplemented with adenine (180 mM), insulin (5 mg/ml), transferrin (5 mg/ml), hydrocortisone (1.1 mM), tri-iodothyronine (2 nM), epinephrine (5.5 mM), epidermal growth factor (1.64 nM) and 10% FCS. Chloride channel activity was assayed by measuring the rate of iodide ( 125 I) efflux. 8 12 CF15 cells were incubated for 2 hours at 37˚C in the presence or absence of either sildenafil or MPB-91 (250 mM). Cells were then washed with efflux buffer containing (in mM): 137 NaCl, 4.4 KCl, 0.3 KH 2 PO 4 , 0.3 NaH 2 PO 4 , 4.2 NaHCO 3 , 1.3 CaCl 2 , 0.5 MgCl 2 , 0.4 MgSO 4 , 5.6 glucose and 10 HEPES, pH 7.5 and incubated in efflux buffer containing 1 mM KI and 1 mCi Na 125 I /ml (NEN, Boston, MA, USA) for 2 hours at 37˚C. Cells were then washed with efflux buffer. After 1 minute the buffer was removed and quickly replaced by 300 ml of the same buffer. The first four aliquots were used to establish a stable baseline in efflux buffer alone. Efflux buffer containing forskolin (10 mM) and genistein (30 mM) to stimulate CFTR activity was used for the remaining aliquots. At the end of the incubation the buffer was recovered and cells solubilised in 1 ml 1 N NaOH. The radioactivity was determined using a gamma counter (Cobra II, Packard Bell).
Analysis of data
For CFTR localisation up to 140 cells for each condition were examined, categorised as having a distinct CFTR location of either near nucleus or apical, and expressed as a percentage of all cells counted. Only ciliated tall columnar epithelial cells were counted as these can be readily differentiated from nonciliated columnar epithelial cells and basal cells, even when DF508-CFTR is localised close to the nucleus.
For CFTR chloride transport activity the fraction of initial intracellular 125 I lost during each time point was determined and time dependent rates (k) of 125 I efflux were calculated from ln ( 125 I t1 / 125 I t2 )/ (t 1 2 t 2 ) where 125 I t is the intracellular 125 I at time t, and t 1 and t 2 are successive time points. 8 12 Curves were constructed by plotting k versus time. Relative rates were calculated and correspond to k peak 2 k basal (per minute). Concentration-response curves were constructed by plotting the percentage activation as a function of the concentration of sildenafil (100% corresponds to the maximum relative rate obtained at the highest concentration, i.e. 1.5 mM). Differences between treated and untreated cells were examined using the Student's t test and p values of ,0.05 were considered significant.
RESULTS
Mislocalisation of DF508-CFTR in CF nasal cells
As in our previous studies, 8 nasal epithelial cells obtained by brushing were polarised with cilia visible at the apical end of the cell that continued to beat for the 2 hour incubation before fixation. The nasal cells expressed cytokeratins typical of epithelial cells throughout the cell. In cells from non-CF individuals, wild type CFTR was located at the apical end of the cell ( fig 1A) . In untreated cells from DF508/ DF508 CF individuals and from a CF individual with the genotype DF508/4016ins, 60-70% of cells showed a near nuclear location of DF508-CFTR with only 10% having DF508-CFTR present at the apical membrane ( fig 1B and  F) . This is in agreement with our previous data on the location of CFTR in wild type, DF508/DF508 and DF508/ G551D cells. 8 Actions of sildenafil on DF508-CFTR location In DF508/DF508 cells treated with sildenafil (150 mM for 2 h at 37˚C), a marked change in DF508-CFTR location was observed ( fig 1C and F) with a significant decrease (p,0.05) in the percentage of cells having a near nuclear location and a significant increase (from 10% to 32%, p,0.05) in cells having DF508-CFTR at the apical membrane. CFTR was also relocated in cells with a single copy DF508 genotype (DF508/4016ins) following sildenafil treatment ( fig 1F) . The data indicate that CFTR trafficking drugs such as sildenafil will be potentially useful in all CF patients carrying a DF508 mutation. Although the concentration of sildenafil effective in increasing DF508-CFTR trafficking is higher than might be achieved in plasma (1 mM) following a single oral dose (100 mg) of Viagra (data from Pfizer: www. ViagraH.com), nevertheless the data show proof of principle for investigating this relatively safe class of compounds for use in CF. Furthermore, the effect of sildenafil was selective in that the distinct locations of endoplasmic reticulum (p115), Golgi (GM130), and 20S proteasome proteins were not altered with sildenafil treatment (data not shown) and sildenafil (150 mM, 2 hours) had no effect on wild type CFTR location ( fig 1A, F) in cells from non-CF individuals.
A new CF trafficking mutation Cells from a CF individual heterozygous for a rare missense mutation, R1283M, 13 and a stop mutation, E60X, were also examined (fig 1D-F) . As for DF508 expressing ., + 500 mM DIDS; X, + 100 mM glibenclamide; $, + 500 mM DPC. (F) Histograms showing the relative rate (k peak 2 k basal ) for the experimental conditions indicated below each bar. ***p,0.001 for difference from cells stimulated by forskolin and genistein (fsk+gst) without the inhibitor; NS, no significant difference. cells, the results (fig 1D, F) showed severe mislocalisation of CFTR with the majority of cells having mutant CFTR within the cell at a site close to the nucleus (near nuclear location). The defective location of this mutant CFTR was also markedly corrected by sildenafil (fig 1E, F) with the majority of treated cells showing an apical CFTR location. This is the first description of R1283M as a trafficking mutation and sildenafil was effective in correcting the defect. The results indicate that trafficking mutations in both the first and second nucleotide binding domains (NBD1 and NBD2) of CFTR are targets for sildenafil.
Effect of sildenafil on CFTR chloride transport activity in CF15 cells
The human airway epithelial CF cell line CF15 was used as a model to study CFTR dependent chloride transport. 11 In untreated CF15 cells there was no stimulation of 125 I efflux in response to the CFTR agonists forskolin and genistein (fig 2A) consistent with its DF508/DF508 CF origin. 11 However, when cells were treated for 2 hours at 37˚C with sildenafil a significant stimulation by forskolin and genistein was recovered (fig 2A and B) . The effect of sildenafil was similar to that of the potent trafficking drug MPB-91, 8 although of lower magnitude. The concentration dependence of the effect of sildenafil treatment showed an EC 50 of 718 (1) mM (fig 2C, D) . Thus, CF15 cells were less sensitive to the effect of sildenafil, requiring a higher concentration than native cells from CF patients to restore function. The effects of a range of Cl 2 channel blockers on the forskolin/genistein stimulated iodide efflux of sildenafil treated cells (1 mM for 2 hours at 37˚C) was determined. The efflux was inhibited by glibenclamide and DPC but not by DIDS or calixarene, demonstrating that sildenafil had recruited functional DF508-CFTR Cl 2 channels at the apical membrane. The results indicate that, like MPB-91, sildenafil was able to restore the chloride channel activity of DF508-CFTR at 37˚C. Immunolocalisation of DF508-CFTR in CF15 cells indicated that, following treatment for 2 hours at 37˚C with 1 mM sildenafil, DF508-CFTR had moved from within the cell to an apical location (data not shown).
DISCUSSION
This study has shown, for the first time, a dramatic and rapid effect of the PDE5 inhibitor sildenafil in directing DF508-CFTR to the apical membrane in native CF airway cells from patients with CF. The effect is comparable to our previously demonstrated effect of MPB compounds. 8 By comparison, other non-selective treatments such as low temperature (25-27˚C), glycerol, or 4-phenylbutyrate have required long term exposure to show modest effects on DF508-CFTR trafficking. 14 The technique that we have developed for confocal immunofluorescence localisation of wild type and DF508-CFTR in native nasal epithelial cells from control and CF individuals allows CFTR location to be visualised in individual cells, the pattern of mislocalisation quantified, and the actions of pharmacological agents on DF508-CFTR trafficking evaluated. In agreement with our previous studies 8 and those of others, 7 9 DF508-CFTR was predominantly mislocalised and present within the cell. DF508-CFTR was detectable at the apical membrane in a minority (approximately 10%) of cells.
The present studies have also identified a new CFTR trafficking mutation in NBD2 (R1283M) that has not previously been investigated. The only other report of altered trafficking of CFTR with a mutation in NBD2 is N1303K. 15 The present results, showing that sildenafil corrects DF508-and R1283M-CFTR location, both mutations in nucleotide binding domains, will provide insights into the mechanism of action of drugs that increase CFTR trafficking. It is noteworthy that neither sildenafil nor MPB compounds affect the trafficking of wild type CFTR, nor of other normal ER or Golgi proteins, thus providing a selective action. We have previously provided evidence 16 that the speed and selectivity of the effect of MPB compounds on DF508-CFTR trafficking is due to direct binding to the CFTR protein at a site within the first cytoplasmic domain. It is therefore possible that sildenafil also binds directly to DF508-CFTR, although an action through cyclic GMP signalling has not been ruled out.
There is agreement that DF508-CFTR has substantial Cl 2 channel activity when present at the apical membrane, which some studies suggest is comparable to that of wildtype CFTR. 1 Thus, the present study showing recruitment of DF508-CFTR to the apical membrane in native CF cells in response to the drug sildenafil, is a major step forward in restoring CFTR function. Although the concentration of sildenafil shown to traffic DF508-CFTR in a CF cell line was higher than in native cells, sensitivities may vary between cell lines, isolated native cells, and in vivo, and this will form the basis of future studies. Nevertheless, the finding that sildenafil, a relatively safe drug already in clinical use, has a dramatic effect in increasing DF508-CFTR trafficking will assist in the discovery of new derivatives and is a major advance towards developing a rational drug treatment aimed at repair or rescue of activity of the mutant CF gene protein. The present results indicate that an approach to drug therapy using CFTR trafficking drugs is likely to be applicable to the majority of patients with CF. 
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